ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2010, Vol. 19 ›› Issue (5): 407-412.

• 论文 • 上一篇    下一篇

肾病综合征患者血浆抗凝血酶III检测及其临床意义

  

  • 出版日期:2010-10-28 发布日期:2010-11-05

Significance of plasma antithrombin III concentraiton in adult nephrotic syndrome patients with different histological patterns

  • Online:2010-10-28 Published:2010-11-05

摘要:

目的: 比较分析不同病理类型肾病综合征患者血浆抗凝血酶IIIantithrombin III, ATIII)浓度的差异及相关影响因素。方法:比较微小病变(minimal change disease, MCDN=26)、局灶节段性肾小球硬化(focal segmental glomerulosclerosis, FSGS, N=26)及膜性肾病(membranous nephropathy, MN, N=20) 三组成人肾病综合征患者肾活检术前血尿ATIII浓度及临床特点。选取20例健康成人作为正常对照。血尿ATIII浓度采用免疫速率比浊法检测。采用PersonSperman方法及多元线性回归分析FSGSMCD患者中影响血浆ATIII浓度的因素。结果:肾活检术时MN组尿蛋白、血清白蛋白、肌酐、总胆固醇、IgGMCDFSGS组差异显著(P<0.05);后两组间这些指标的差异无统计学意义(P> 0.05)。FSGS组尿C3α2巨球蛋白、N-乙酰-β-D-葡萄糖苷酶、视黄醇结合蛋白高于MCDMN(P<0.05)26(100%) MCD23(88.46%) FSGS3(15%) MN患者血浆ATIII降低( P<0.05)FSGSMCD患者血浆ATIII浓度分别15.64±3.86mg/dL18.10±4.8mg/dL(P<0.05),均低于MN患者28.08±4.23mg/dL (P<0.05)FSGSMCD组尿ATIII>5mg/dl者分别为8/20例(40%)、4/22(18.18%)P>0.05),而MN组患者尿液ATIII含量均<5mg/dl (P<0.05)一元回归发现FSGS患者中血浆ATIII浓度与尿蛋白(r=-0.505,P<0.05)负相关、血清白蛋白(r=0.559, P <0.01)正相关;MCD患者中血浆ATIII浓度与尿蛋白(r=-0.429, P<0.05)负相关,与血清白蛋白(r=0.564P<0.01)IgG(r=0.529, P<0.01)正相关。多元回归分析提示FSGSMCD患者中血浆ATIII与血清白蛋白相关(R2= 0.3120.320P<0.05)随访中2ATIII降低的FSGS患者发生静脉血栓。结论:肾病综合征患者血浆ATIII浓度与病理类型有关。FSGS MCD血浆ATIII浓度较MN明显下降,可能源于尿液丢失的差异。

Abstract:

Objective: To compare plasma antithrombin III (ATIII) concentration and related factors in adult nephrotic syndrome patients with different histological patterns. Methodology: Seventy-two adult nephrotic syndrome patients with different histological patterns were enrolled in this study. They were minimal change disease (MCD, n=26), focal segmental glomerulosclerosis (FSGS, n=26) and membranous nephropahty (MN, n=20). 20 healthy adults served as normal control. The blood and urinary samples were collected before renal biopsy. The levels of plasma and urine ATIII were detected by immune rate nephelometry. The clinical characteristics at biopsy, plasma and urinary ATIII were compared. The factors related to plasma ATIII were analyzed by PersonSpearman methods, followed by multi-linear regression. Results: The levels of serum albuminin, creatinine, total cholesterol, IgG and proteinuria at biopsy in MN group were significantly different from FSGS and MCD group (P<0.05). The difference of these variables were not significant between FSGS and MCD group P>0.05. The levels of urinary C3, α2 macroglobulinN-acetyl-β-D-glucosaminidaseand retinol binding protein in FSGS group were higher than those in MCD and MN group (P<0.05). The plasma level of ATIII concentration in FSGS and MCD were 15.64±3.86mg/dL and 18.10±4.8mg/dL (P<0.05) , respectively, which were less than that in MN (28.08±4.23mg/dL). The plasma level of ATIII was decreased in 26 cases (100%) of MCD, 23 (88.4%) of FSGS and 3 (15%) of MN (P<0.05). The level of urinary ATIII was increased in 8 cases of 20 FSGS, 4 of 22 MCD and none of MN (P <0.05). The plasma ATIII in FSGS group was correlated with serum albumin positively (r=0.559, P<0.01), and proteinuria negatively (r=-0.505, P<0.05). Similarly, the plasma ATIII in MCD group was correlated with serum albumin ( r=0.564P<0.05) and IgG (r=0.529, P<0.05) positively, and proteinuria (r=-0.429, P<0.05) negatively. Multi-linear regression showed that serum albumin was an independent factor in both FSGS and MCD with decreasing plasma ATIII (R2 0.3120.320P<0.05. During the follow-up, two FSGS patients with lower ATIII concentration had venous thrombosis attack. ConclusionThe level of plasma ATIII in patients with nephrotic syndrome was related to the underlying renal diseases. The plasma ATIII concentration was much lower in FSGS and MCD than that in MN, which may be secondary to the differential urinary loss.